Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-10-7
pubmed:abstractText
It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and possible efficacy advantages over traditional systemic treatments. These biologic drugs are also considerably more expensive than traditional treatments (up to approximately US$30,000 per patient per year). The treatment of psoriasis and other inflammatory skin diseases with biologics could place a significant burden on the healthcare delivery system. In addition to judicious use of biologics, it is the task of the dermatology community to encourage healthcare delivery systems to eliminate the impediments to safe, effective and lower cost treatments such as phototherapy. Appropriate patient selection for biologic therapies is paramount. The goal of therapy for patients with psoriasis is to alleviate suffering in a cost-effective manner for the patient and the healthcare system as a whole. Much has been written on the use of biologic therapies for psoriasis and in this review the authors offer their perspective on the place of biologics in the psoriasis armamentarium.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Oct
pubmed:issn
1744-8379
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
573-9
pubmed:year
2004
pubmed:articleTitle
Management and costs of severe psoriasis: the role of new biologics.
pubmed:affiliation
Wake Forest University, Department of Dermatology, School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071, USA. sfeldman@wfubmc.edu
pubmed:publicationType
Journal Article